Ion channelopathies in endocrinology: Recent genetic findings and pathophysiological insights;canalopatias em endocrinologia: Achados genéticos recentes e fisiopatologia

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 54, Issue 8, 2010, Pages 673-681

  Rolim, Ana Luiza R ^a   Lindsey, Susan C ^a   Kunii, Ilda S ^a   Fujikawa, Aline M ^a   Soares, Fernando A ^a   Chiamolera, Maria Izabel ^a   Maciel, Rui M B ^a   Dias da Silva, Magnus R ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Channelopathy; Endocrine channelopathy; Ion channel

Indexed keywords

EID: 79951932749     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302010000800002     Document Type: Review

References (60)

1. Hille B. Ion channels of excitable membranes. 3rd ed. Sunderland, Mass.: Sinauer; 2001.
2. Sherwood L, Cengage Learning (Firm). Human physiology: from cells to systems. 7th ed. Australia; United States: Brooks/Cole, Cengage Learning; 2010.
3. Ozawa S, Sand O. Electrophysiology of excitable endocrine cells. Physiol Rev. 1986;66(4):887-952.
4. Dunne MJ, Cosgrove KE, Shepherd RM, Aynsley-Green A, Lindley KJ. Hyperinsulinism in infancy: from basic science to clinical disease. Physiol Rev. 2004;84(1):239-75.
5. Olson TM, Terzic A. Human K(ATP) channelopathies: diseases of metabolic homeostasis. Pflugers Arch. 2010;460(2):295-306.
6. Kukuljan M, Rojas E, Catt KJ, Stojilkovic SS. Membrane potential regulates inositol 1,4,5-trisphosphate-controlled cytoplasmic Ca2+ oscillations in pituitary gonadotrophs. J Biol Chem. 1994;269(7):4860-5.
7. Li YX, Rinzel J, Vergara L, Stojilkovic SS. Spontaneous electrical and calcium oscillations in unstimulated pituitary gonadotrophs. Biophys J. 1995;69(3):785-95.
8. Van Goor F, Zivadinovic D, Stojilkovic SS. Differential expression of ionic channels in rat anterior pituitary cells. Mol Endocrinol. 2001;15(7):1222-36.
9. Ballaro B, Reas PG, Riccardi R. Mathematical models for excitable systems in biology and medicine. Riv Biol. 2007;100(2):247-66.
10. Kunz L, Thalhammer A, Berg FD, Berg U, Duffy DM, Stouffer RL, et al. Ca2+-activated, large conductance K+ channel in the ovary: identification, characterization, and functional involvement in steroidogenesis. J Clin Endocrinol Metab. 2002;87(12):5566-74.
11. Silva MR, Chiamolera MI, Kasamatsu TS, Cerutti JM, Maciel RM. [Thyrotoxic hypokalemic periodic paralysis, an endocrine emergency: clinical and genetic features in 25 patients]. Arq Bras Endocrinol Metabol. 2004 48(1):196-215.
12. Dias da Silva MR, Cerutti JM, Arnaldi LA, Maciel RM. A mutation in the KCNE3 potassium channel gene is associated with susceptibility to thyrotoxic hypokalemic periodic paralysis. J Clin Endocrinol Metab. 2002;87(11):4881-4.
13. Dias da Silva MR, Cerutti JM, Tengan CH, Furuzawa GK, Vieira TC, Gabbai AA, et al. Mutations linked to familial hypokalaemic periodic paralysis in the calcium channel alpha1 subunit gene (Cav1.1) are not associated with thyrotoxic hypokalaemic periodic paralysis. Clin Endocrinol (Oxf). 2002;56(3):367-75.
14. Ng WY, Lui KF, Thai AC, Cheah JS. Absence of ion channels CACN1AS and SCN4A mutations in thyrotoxic hypokalemic periodic paralysis. Thyroid. 2004;14(3):187-90.
15. Ryan DP, Dias da Silva MR, Soong TW, Fontaine B, Donaldson MR, Kung AW, et al. Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis. Cell. 2010;140(1):88-98.
16. Nehring RB, Wischmeyer E, Doring F, Veh RW, Sheng M, Karschin A. Neuronal inwardly rectifying K(+) channels differentially couple to PDZ proteins of the PSD-95/SAP90 family. J Neurosci. 2000;20(1):156-62.
17. Fernandes-Rosa FL, Antonini SR. [Mineralocorticoid resistance: pseudohypoaldosteronism type 1]. Arq Bras Endocrinol Metabol. 2007;51(3):373-81.
18. Riepe FG. Clinical and molecular features of type 1 pseudohypoaldosteronism. Horm Res. 2009;72(1):1-9.
19. Geller DS. Mineralocorticoid resistance. Clin Endocrinol (Oxf). 2005;62(5):513-20.
20. Chang SS, Grunder S, Hanukoglu A, Rosler A, Mathew PM, Hanukoglu I, et al. Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type 1. Nat Genet. 1996;12(3):248-53.
21. Shimkets RA, Warnock DG, Bositis CM, Nelson-Williams C, Hansson JH, Schambelan M, et al. Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell. 1994;79(3):407-14.
22. Hansson JH, Nelson-Williams C, Suzuki H, Schild L, Shimkets R, Lu Y, et al. Hypertension caused by a truncated epithelial sodium channel gamma subunit: genetic heterogeneity of Liddle syndrome. Nat Genet. 1995;11(1):76-82.
23. Drager LF, Krieger JE. [Genetic aspects of endocrine hypertensive disorders]. Arq Bras Endocrinol Metabol. 2004;48(5):659-65.
24. Martinez-Aguayo A, Fardella C. Genetics of hypertensive syndrome. Horm Res. 2009;71(5):253-9.
25. Vehaskari VM. Heritable forms of hypertension. Pediatr Nephrol. 2009;24(10):1929-37.
26. Walder RY, Landau D, Meyer P, Shalev H, Tsolia M, Borochowitz Z, et al. Mutation of TRPM6 causes familial hypomagnesemia with secondary hypocalcemia. Nat Genet. 2002;31(2):171-4.
27. Schlingmann KP, Weber S, Peters M, Niemann Nejsum L, Vitzthum H, Klingel K, et al. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nat Genet. 2002;31(2):166-70.
28. Nozu K, Iijima K, Kanda K, Nakanishi K, Yoshikawa N, Satomura K, et al. The Pharmacological characteristics of molecular-based inherited salt-losing tubulopathies. J Clin Endocrinol Metab. 2010;95(12):E511-8.
29. Kleta R, Bockenhauer D. Bartter syndromes and other salt-losing tubulopathies. Nephron Physiol. 2006;104(2):73-80.
30. Simon DB, Karet FE, Rodriguez-Soriano J, Hamdan JH, DiPietro A, Trachtman H, et al. Genetic heterogeneity of Bartter's syndrome revealed by mutations in the K+ channel, ROMK. Nat Genet. 1996;14(2):152-6.
31. Simon DB, Bindra RS, Mansfield TA, Nelson-Williams C, Mendonca E, Stone R, et al. Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome type III. Nat Genet. 1997;17(2):171-8.
32. L. The calcium-sensing receptor and related diseases. Arq Bras Endocrinol Metabol. 2006;50(4):628-39.
33. Hussain K. Diagnosis and management of hyperinsulinaemic hypoglycaemia of infancy. Horm Res. 2008;69(1):2-13.
34. Thomas PM, Cote GJ, Wohllk N, Haddad B, Mathew PM, Rabl W, et al. Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. Science. 1995;268(5209):426-9.
35. Thomas P, Ye Y, Lightner E. Mutation of the pancreatic islet inward rectifier Kir6.2 also leads to familial persistent hyperinsulinemic hypoglycemia of infancy. Hum Mol Genet. 1996;5(11):1809-12.
36. Aguilar-Bryan L, Bryan J. Neonatal diabetes mellitus. Endocr Rev. 2008;29(3):265-91.
37. Gurgel LC, Moises RS. [Neonatal diabetes mellitus]. Arq Bras Endocrinol Metabol. 2008;52(2):181-7.
38. Ratjen F, Doring G. Cystic fibrosis. Lancet. 2003;361(9358):681-9.
39. Rana M, Munns CF, Selvadurai H, Donaghue KC, Craig ME. Cystic fibrosis-related diabetes in children--gaps in the evidence? Nat Rev Endocrinol. 2010;6(7):371-8.
40. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245(4922):1066-73.
41. Dorfman R, Sandford A, Taylor C, Huang B, Frangolias D, Wang Y, et al. Complex two-gene modulation of lung disease severity in children with cystic fibrosis. J Clin Invest. 2008;118(3):1040-9.
42. The Cystic Fibrosis Genetic Analysis Consortium. Cystic Fibrosis Mutation Data Base. [Nov 26, 2010]. Available from: http://www. genet.sickkids.on.ca/cftr
43. Southern KW, Merelle MM, Dankert-Roelse JE, Nagelkerke AD. Newborn screening for cystic fibrosis. Cochrane Database Syst Rev. 2009(1):CD001402.
44. Wrong OM, Norden AG, Feest TG. Dent's disease; a familial proximal renal tubular syndrome with low-molecular-weight proteinuria, hypercalciuria, nephrocalcinosis, metabolic bone disease, progressive renal failure and a marked male predominance. QJM. 1994;87(8):473-93.
45. Scheinman SJ. X-linked hypercalciuric nephrolithiasis: clinical syndromes and chloride channel mutations. Kidney Int. 1998;53(1):3-17.
46. Fisher SE, van Bakel I, Lloyd SE, Pearce SH, Thakker RV, Craig IW. Cloning and characterization of CLCN5, the human kidney chloride channel gene implicated in Dent disease (an X-linked hereditary nephrolithiasis). Genomics. 1995;29(3):598-606.
47. Gunther W, Luchow A, Cluzeaud F, Vandewalle A, Jentsch TJ. ClC- 5, the chloride channel mutated in Dent's disease, colocalizes with the proton pump in endocytotically active kidney cells. Proc Natl Acad Sci U S A. 1998;95(14):8075-80.
48. Hoopes Jr RR, Shrimpton AE, Knohl SJ, Hueber P, Hoppe B, Matyus J, et al. Dent disease with mutations in OCRL1. Am J Hum Genet. 2005;76(2):260-7.
49. Kronenberg H, Williams RH. Williams textbook of endocrinology. 11th ed. Philadelphia: Saunders/Elsevier; 2008.
50. Kornak U, Kasper D, Bosl MR, Kaiser E, Schweizer M, Schulz A, et al. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell. 2001;104(2):205-15.
51. Tolar J, Teitelbaum SL, Orchard PJ. Osteopetrosis. N Engl J Med. 2004;351(27):2839-49.
52. Benichou OD, Laredo JD, de Vernejoul MC. Type II autosomal dominant osteopetrosis (Albers-Schonberg disease): clinical and radiological manifestations in 42 patients. Bone. 2000;26(1):87-93.
53. Askmyr M, Flores C, Fasth A, Richter J. Prospects for gene therapy of osteopetrosis. Curr Gene Ther. 2009;9(3):150-9.
54. Garofeanu CG, Weir M, Rosas-Arellano MP, Henson G, Garg AX, Clark WF. Causes of reversible nephrogenic diabetes insipidus: a systematic review. Am J Kidney Dis. 2005;45(4):626-37.
55. Sasaki S. Nephrogenic diabetes insipidus: update of genetic and clinical aspects. Nephrol Dial Transplant. 2004;19(6):1351-3.
56. van Lieburg AF, Verdijk MA, Knoers VV, van Essen AJ, Proesmans W, Mallmann R, et al. Patients with autosomal nephrogenic diabetes insipidus homozygous for mutations in the aquaporin 2 water-channel gene. Am J Hum Genet. 1994;55(4):648-52.
57. Kozono D, Yasui M, King LS, Agre P. Aquaporin water channels: atomic structure molecular dynamics meet clinical medicine. J Clin Invest. 2002;109(11):1395-9.
58. Yang B, Zhao D, Verkman AS. Hsp90 inhibitor partially corrects nephrogenic diabetes insipidus in a conditional knock-in mouse model of aquaporin-2 mutation. FASEB J. 2009;23(2):503-12.
59. Schwarz JR, Bauer CK. Functions of erg K+ channels in excitable cells. J Cell Mol Med. 2004;8(1):22-30.
60. Vincent JD, Kukstas LA, Lledo PM. Endocrine cell excitability opens the way to novel pharmacological intervention: example of the anterior pituitary cell. Cell Biol Toxicol. 1992;8(3):85-91.